ELI LILLY AND COMPANY Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate
ELI LILLY AND COMPANY (LLY) had Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate of 4.00% as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Notes › Debt
us-gaap:LongTermDebtPercentageBearingVariableInterestRate · last filed 2025-10-30
- 2025-09-30: Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate 4.00%.
- 2025-06-30: Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate 5.00%.
- 2025-03-31: Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate 5.00%.
- 2024-12-31: Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate 5.00%.
| Period end | Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate | Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate as first filed |
|---|---|---|
| 2025-09-30 | 4.00% 10-Q · filed 2025-10-30 | |
| 2025-06-30 | 5.00% 10-Q · filed 2025-08-07 | |
| 2025-03-31 | 5.00% 10-Q · filed 2025-05-01 | |
| 2024-12-31 | 5.00% 10-K · filed 2025-02-19 | |
| 2024-09-30 | 5.00% 10-Q · filed 2024-10-30 | |
| 2024-06-30 | 8.00% 10-Q · filed 2024-08-08 | |
| 2024-03-31 | 8.00% 10-Q · filed 2024-04-30 | |
| 2023-12-31 | 12.00% 10-K · filed 2024-02-21 | |
| 2023-09-30 | 12.00% 10-Q · filed 2023-11-02 | |
| 2023-06-30 | 12.00% 10-Q · filed 2023-08-08 | |
| 2023-03-31 | 12.00% 10-Q · filed 2023-04-27 | |
| 2022-12-31 | 10.00% 10-K · filed 2023-02-22 | |
| 2021-12-31 | 13.00% 10-K · filed 2022-02-23 | |
| 2020-12-31 | 9.00% 10-K · filed 2021-02-17 | |
| 2019-12-31 | 11.00% 10-K · filed 2020-02-19 | |
| 2018-12-31 | 25.00% 8-K · filed 2019-10-24 | 20.00% 10-K · filed 2019-02-19 |
| 2017-12-31 | 28.00% 10-K · filed 2018-02-20 | |
| 2016-12-31 | 35.00% 10-K · filed 2017-02-21 | |
| 2015-12-31 | 40.00% 10-K · filed 2016-02-19 | |
| 2014-12-31 | 55.00% 10-K · filed 2015-02-19 | |
| 2013-12-31 | 65.00% 10-K · filed 2014-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |